{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:04:22Z","timestamp":1778720662954,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T00:00:00Z","timestamp":1310428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T00:00:00Z","timestamp":1310428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1038\/tpj.2011.28","type":"journal-article","created":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T10:10:35Z","timestamp":1310465435000},"page":"507-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine"],"prefix":"10.1038","volume":"12","author":[{"given":"S","family":"Ono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Tsuneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Someya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,12]]},"reference":[{"key":"BFtpj201128_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.173.1.11","volume":"173","author":"EC Harris","year":"1998","unstructured":"Harris EC, Barraclough B . Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11\u201353.","journal-title":"Br J Psychiatry"},{"key":"BFtpj201128_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","volume":"26","author":"L Dixon","year":"2000","unstructured":"Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903\u2013912.","journal-title":"Schizophr Bull"},{"key":"BFtpj201128_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SA, Sullivan L et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19\u201332.","journal-title":"Schizophr Res"},{"key":"BFtpj201128_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01317.x","volume":"119","author":"JM Meyer","year":"2009","unstructured":"Meyer JM, Stahl SM . The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119: 4\u201314.","journal-title":"Acta Psychiatr Scand"},{"key":"BFtpj201128_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"J Lieberman","year":"2005","unstructured":"Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209\u20131223.","journal-title":"N Engl J Med"},{"key":"BFtpj201128_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","volume":"64","author":"K Melkersson","year":"2004","unstructured":"Melkersson K, Dahl ML . Adverse metabolic effects associated with atypical antipsychotics\u2014literature review and clinical implications. Drugs 2004; 64: 701\u2013723.","journal-title":"Drugs"},{"key":"BFtpj201128_CR7","first-page":"36","volume":"65","author":"JW Newcomer","year":"2004","unstructured":"Newcomer JW . Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 36\u201346.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201128_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW . Second-generation (atypical) antipsychotics and metabolic effects\u2014a comprehensive literature review. CNS Drugs 2005; 19: 1\u201393.","journal-title":"CNS Drugs"},{"key":"BFtpj201128_CR9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/070674370605100803","volume":"51","author":"JW Newcomer","year":"2006","unstructured":"Newcomer JW, Haupt DW . The metabolic effects of antipsychotic medications. Can J Psychiatry Revue Canadienne De Psychiatrie 2006; 51: 480\u2013491.","journal-title":"Can J Psychiatry Revue Canadienne De Psychiatrie"},{"key":"BFtpj201128_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71\u201393.","journal-title":"Schizophr Bull"},{"key":"BFtpj201128_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment\u2014insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia 1985; 28: 412\u2013419.","journal-title":"Diabetologia"},{"key":"BFtpj201128_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","volume":"59","author":"JW Newcomer","year":"2002","unstructured":"Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337\u2013345.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj201128_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.4088\/JCP.08m04132","volume":"70","author":"J Newcomer","year":"2009","unstructured":"Newcomer J, Ratner R, Eriksson J, Emsley R, Meulien D, Miller F et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009; 70: 487\u2013499.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201128_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4088\/JCP.07m03829","volume":"70","author":"N Yasui-Furukori","year":"2009","unstructured":"Yasui-Furukori N, Sato Y, Furukori H, Saito M, Nakagami T, Kaneko S . Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. J Clin Psychiatry 2009; 70: 95\u2013100.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201128_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.schres.2008.09.008","volume":"106","author":"L Hanssens","year":"2008","unstructured":"Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Reginster J et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008; 106: 308\u2013314.","journal-title":"Schizophr Res"},{"key":"BFtpj201128_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ . The biology of incretin hormones. Cell Metabol 2006; 3: 153\u2013165.","journal-title":"Cell Metabol"},{"key":"BFtpj201128_CR17","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","volume":"287","author":"JJ Holst","year":"2004","unstructured":"Holst JJ, Gromada J . Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metabol 2004; 287: E199\u2013E206.","journal-title":"Am J Physiol Endocrinol Metabol"},{"key":"BFtpj201128_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/ng.521","volume":"42","author":"R Saxena","year":"2010","unstructured":"Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142\u2013U175.","journal-title":"Nat Genet"},{"key":"BFtpj201128_CR19","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/dme.1996.13.s6.13","volume":"13","author":"HK Min","year":"1996","unstructured":"Min HK . Non-insulin-dependent diabetes mellitus (NIDDM) in Korea. Diabetic Med 1996; 13: S13\u2013S15.","journal-title":"Diabetic Med"},{"key":"BFtpj201128_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/FTD.0b013e318038d835","volume":"29","author":"N Fukui","year":"2007","unstructured":"Fukui N, Suzuki Y, Sawamura K, Sugai T, Watanabe J, Inoue Y et al. Dose-dependent effects of the 3435 C&gt;T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 2007; 29: 185\u2013189.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201128_CR21","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1210\/jc.2002-021873","volume":"88","author":"T Vilsboll","year":"2003","unstructured":"Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metabol 2003; 88: 2706\u20132713.","journal-title":"J Clin Endocrinol Metabol"},{"key":"BFtpj201128_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/070674370605100608","volume":"51","author":"TA Cohn","year":"2006","unstructured":"Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TMS . Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry Revue Canadienne De Psychiatrie 2006; 51: 382\u2013386.","journal-title":"Can J Psychiatry Revue Canadienne De Psychiatrie"},{"key":"BFtpj201128_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","volume":"24","author":"LM Spelman","year":"2007","unstructured":"Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH . Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Med 2007; 24: 481\u2013485.","journal-title":"Diabetic Med"},{"key":"BFtpj201128_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4088\/JCP.v61n1006","volume":"61","author":"KI Melkersson","year":"2000","unstructured":"Melkersson KI, Hulting AL, Brismar KE . Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742\u2013749.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201128_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0924-977X(03)00072-5","volume":"14","author":"K Melkersson","year":"2004","unstructured":"Melkersson K . Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004; 14: 115\u2013119.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFtpj201128_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","volume":"62","author":"DC Henderson","year":"2005","unstructured":"Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19\u201328.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj201128_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4088\/JCP.v69n0320","volume":"69","author":"R van Winkel","year":"2008","unstructured":"van Winkel R, De Hert M, Wampers M, Van Eyck D, Hanssens L, Scheen A et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008; 69: 472\u2013479.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201128_CR28","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","volume":"70","author":"RC Smith","year":"2009","unstructured":"Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry 2009; 70: 1501\u20131513.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201128_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/sj.tpj.6500346","volume":"6","author":"S Sondhi","year":"2006","unstructured":"Sondhi S, Castellano JM, Chong VZ, Rogoza RM, Skoblenick KJ, Dyck BA et al. CDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects. Pharmacogenomics J 2006; 6: 131\u2013140.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201128_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4088\/JCP.0807e20","volume":"68","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW . Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68: 20\u201327.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201128_CR31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1210\/jcem-51-3-520","volume":"51","author":"RP Eaton","year":"1980","unstructured":"Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J . Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 1980; 51: 520\u2013528.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtpj201128_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1172\/JCI112308","volume":"77","author":"KS Polonsky","year":"1986","unstructured":"Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986; 77: 98\u2013105.","journal-title":"J Clin Invest"},{"key":"BFtpj201128_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1109\/10.488799","volume":"43","author":"G Sparacino","year":"1996","unstructured":"Sparacino G, Cobelli C . A stochastic deconvolution method to reconstruct insulin secretion rate after a glucose stimulus. IEEE Trans Biomed Eng 1996; 43: 512\u2013529.","journal-title":"IEEE Trans Biomed Eng"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201128","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:27:40Z","timestamp":1647944860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["BFtpj201128"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2011.28","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,12]]},"assertion":[{"value":"16 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}